Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NexgenRxNEGXF -87.38%50 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2026, which is 129% above its 10-year median of 10.10. GuruFocus rates NEGXF with a GF Score™ of 50/100 and a GF Value™ of $0.17. The stock has 6 warning signs investors should review. Among 523 Healthcare Providers & Services companies, NexgenRx ranks better than 70.55% on this metric.
During the past 12 months, NexgenRx's average EBITDA Per Share Growth Rate was 52.80% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 23.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of NexgenRx was 55.50% per year. The lowest was -35.70% per year. And the median was 10.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
NexgenRx 3-Year EBITDA Growth Rate Related Terms
NEGXF vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, NexgenRx's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NexgenRx 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where NexgenRx's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 23.10% mean?
NexgenRx (NEGXF) has a 3-Year EBITDA Growth Rate of 23.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NexgenRx and its competitors. This is 129% above median its historical median of 10.10. According to the industry distribution chart, NexgenRx ranks #154 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 29.4%.
Is NexgenRx's 3-Year EBITDA Growth Rate too high?
NexgenRx's current 3-Year EBITDA Growth Rate of 23.10% is 129% above median its 10-year median of 10.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. NexgenRx's value of 23.10% is 133.3% above this industry median. Based on the distribution chart, NexgenRx ranks #154 out of 523 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NexgenRx has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #154 out of 523 companies for 3-Year EBITDA Growth Rate. This puts NexgenRx in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 9.90. NexgenRx's value of 23.10% is 133.3% above this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 9.90, NexgenRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NexgenRx's current 3-Year EBITDA Growth Rate of 23.10% is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for NexgenRx and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NexgenRx's current 3-Year EBITDA Growth Rate is 23.10%, which is 129% above median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
NexgenRx (NEGXF) has a current 3-Year EBITDA Growth Rate of 23.10%. The stock's GF Value™ is $0.17, compared to a current price of $0.04 — trading 75.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 23.10%, which is 129% above median its 10-year median of 10.10 and 133.3% above the Healthcare Providers & Services industry median of 9.90. NexgenRx's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For NexgenRx (NEGXF), the current 3-Year EBITDA Growth Rate is 23.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NexgenRx (NEGXF) Overvalued in 2026?
Based on GuruFocus' analysis, NexgenRx stock appears to be undervalued.
The current stock price of $0.04 is trading 75.9% below its estimated GF Value™ of $0.17.
Key valuation signals for NEGXF:
3-Year EBITDA Growth Rate: 23.10% (129% above median its 10-year median of 10.10)
GF Value™: $0.17 vs. price of $0.04 (75.9% below fair value)
Industry Position: 133.3% above the Healthcare Providers & Services median (#154 of 523)
No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
50GF Score
Get the complete analysis for NEGXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEGXF has been successfully added to your 
